Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Rose who wrote (109201)	9/29/2000 11:13:38 AM
From: 10K a day	Respond to of 164684

Dude I don't think he cares. I think he went to the beach... -g-

To: Robert Rose who wrote (109201)	9/29/2000 11:42:38 AM
From: H James Morris	Read Replies (1) \| Respond to of 164684

Rob, not a good environment to go shopping in but I did buy some Gnom today. >NEW YORK, Sept 29 (Reuters) - Genomica Corp. <GNOM.O>, which makes software to assist pharmaceutical and biotechnology research, said Friday it priced 6.44 million shares at $19 per share in an initial public offering, above a price range that had already been raised. On Sept. 5, the company raised the range to $16-$17 per share from a $15-$17 per share range. Boulder, Colo.-based Genomica raised $122.4 million through the offering. The company will use proceeds to continue development of its existing and new products, to expand sales and marketing activities, for possible acquisitions, to repay lease obligations and for general corporate purposes. Genomica said its lead product, Discovery Manager, allows researchers to turn the vast volumes of gene, protein and patient data into information useful for drug discovery. CIBC World Markets was lead underwriter for Genomica, which will trade under the symbol GNOM. 10:04 09-29-00